Mark DiPaolo Net Worth

Mark DiPaolo biography

Mark A. DiPaolo Esq. serves as Independent Director of the Company. He has served as a member of our Board of Directors since February 2018 and is currently a member of the Compensation Committee and the Nominating/Corporate Governance Committee of the Board of Directors (the "Nominating/Corporate Governance Committee"). Mr. DiPaolo has been a Partner and the General Counsel of Sarissa Capital Management LP, a registered investment advisor, since May 2013. Sarissa Capital Management LP focuses on improving the strategies of companies to enhance shareholder value. From 2005 - 2013, Mr. DiPaolo served as a senior member of Icahn Capital's investment team, working on all aspects of Carl Icahn's activist investment strategy. Prior to working with Icahn Capital, Mr. DiPaolo was an attorney with Willkie Farr & Gallagher LLP. Mr. DiPaolo previously served as a member of the board of directors of Novelion Therapeutics, Inc., a publicly traded biopharmaceutical company. Mr. DiPaolo received his B.A. degree from Fordham University and his J.D. degree from Georgetown University. Mr. DiPaolo's substantial experience in operations, transactions, law and corporate governance and knowledge of our field contributed to our conclusion that he should serve as a director.

What is the salary of Mark DiPaolo?

As the Independent Director of Innoviva Inc, the total compensation of Mark DiPaolo at Innoviva Inc is $289,994. There are 7 executives at Innoviva Inc getting paid more, with Marianne Zhen having the highest compensation of $551,918.

How old is Mark DiPaolo?

Mark DiPaolo is 49, he's been the Independent Director of Innoviva Inc since 2018. There are 5 older and 2 younger executives at Innoviva Inc. The oldest executive at Innoviva Inc is Jules Haimovitz, 69, who is the Independent Director.

What's Mark DiPaolo's mailing address?

Mark's mailing address filed with the SEC is 1350 OLD BAYSHORE HIGHWAY, SUITE 400, , BURLINGAME, CA, 94010.

Insiders trading at Innoviva Inc

Over the last 9 years, insiders at Innoviva Inc have traded over $394,127,811 worth of Innoviva Inc stock and bought 682,000 units worth $8,768,520 . The most active insiders traders include Plc Gsk, Alexander J Sarissa Capital... és Patrick G Lepore. On average, Innoviva Inc executives and independent directors trade stock every 78 days with the average trade being worth of $18,199,955. The most recent stock trade was executed by Marianne Zhen on 15 November 2023, trading 10,994 units of INVA stock currently worth $153,806.

What does Innoviva Inc do?

innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. innoviva's portfolio is anchored by the respiratory assets partnered with glaxo group limited (gsk), including relvar®/breo® ellipta® and anoro® ellipta®, which were jointly developed by innoviva and gsk. under the agreement with gsk, innoviva is eligible to receive associated royalty revenues from relvar®/breo® ellipta®, anoro® ellipta® and, if approved and commercialized, vi monotherapy, as well. in addition, innoviva retains a 15 percent economic interest in future payments made by gsk for earlier-stage programs partnered with theravance biopharma, inc. for more information, please visit innoviva's website at www.inva.com.

Innoviva Inc executives and stock owners

Innoviva Inc executives and other stock owners filed with the SEC include:

• Marianne Zhen,
  Chief Accounting Officer
• Marianne Zhen CPA,
  Chief Accounting Officer
• Pavel Raifeld C.F.A.,
  Chief Exec. Officer
• George Bickerstaff,
  Independent Director
• Jules Haimovitz,
  Independent Director
• Odysseas Kostas,
  Independent Chairman of the Board
• Sarah Schlesinger,
  Independent Director
• Mark DiPaolo,
  Independent Director
• Pavel Raifeld,
  Chief Executive Officer
• Paul Pepe,
  Director
• Michael W Aguiar,
  President & Chief Exec Officer
• Barbara Gayle Duncan,
  Director
• William H Waltrip,
  Director
• Theodore L Jr Witek,
  Sr. VP & Chief Scientific Off.
• Cathy Friedman,
  Director
• James L Tyree,
  Director
• Michael E. Faerm,
  Sr VP & Chief Business Officer
• George B Abercrombie,
  Sr. VP & Chief Comm. Officer
• Patrick G Lepore,
  Director
• Eric D Esparbes,
  SVP and CFO
• Alexander J Sarissa Capital...,
  
• Matthew Ronsheim,
  See Remarks
• Geoffrey Hulme,
  Interim Principal Exec Officer
• Deborah Birx,
  Director
• Plc Gsk,
  10% owner
• Derek A Small,
  Director
• Sapna Srivastava,
  Director
• Margaret Koziel,
  Chief Medical Officer
• Stephen Basso,
  Chief Financial Officer